<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399885</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6973</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Infection and drug resistance</Title><ISOAbbreviation>Infect Drug Resist</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID-19: A Propensity Score-Matched Analysis.</ArticleTitle><Pagination><StartPage>4317</StartPage><EndPage>4325</EndPage><MedlinePgn>4317-4325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IDR.S481591</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Azvudine is used to treat patients with the coronavirus disease 2019 (COVID-19). This study evaluated the clinical efficacy of azvudine in hospitalized patients with different severities of COVID-19 because few studies have described this in patients with severe and non-severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective study included hospitalized patients with COVID-19 in Guizhou Provincial People's Hospital between December 2022 and January 2023. Azvudine-treated patients and controls were matched for sex, age, and disease severity at admission. Laboratory results and outcomes, including all-cause mortality, invasive mechanical ventilation, intensive care unit admission, and hospital stay length, were evaluated. Stratified analysis was used to explore the difference in the efficacy of azvudine in severe and non-severe COVID-19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">No significant differences in all-cause mortality were observed between the 303 azvudine recipients and 303 matched controls. However, azvudine-treated patients had shorter hospital stays (8.34±4.79 vs 9.17±6.25 days, P=0.046) and higher lymphocyte improvement rates (21.5% vs 13.9%, P=0.019), with a more pronounced effect in patients with non-severe COVID-19 (length of hospital stay, 8.07±4.35 vs 10.00±6.29 days, P=0.001; lymphocyte improvement rate, 23.8% vs 12.8%, P=0.015).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Azvudine treatment shortens hospital stay length and increases the rate of lymphocyte count improvement in patients with non-severe COVID-19, suggesting that azvudine may be a treatment option for these patients.</AbstractText><CopyrightInformation>© 2024 Zhang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Siqin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-0174-8065</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tan</LastName><ForeName>Songsong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-2259-9059</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Central Laboratory, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yaoyao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Guohang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fengjiao</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research Department, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1947-0809</Identifier><AffiliationInfo><Affiliation>Department of Respiratory and Critical Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Pulmonary Immunological Diseases (Guizhou Provincial People's Hospital), Guiyang, Guizhou, 550002, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Drug Resist</MedlineTA><NlmUniqueID>101550216</NlmUniqueID><ISSNLinking>1178-6973</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">azvudine</Keyword><Keyword MajorTopicYN="N">clinical outcome</Keyword><Keyword MajorTopicYN="N">effectiveness</Keyword><Keyword MajorTopicYN="N">hospital stay length</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399885</ArticleId><ArticleId IdType="pmc">PMC11469939</ArticleId><ArticleId IdType="doi">10.2147/IDR.S481591</ArticleId><ArticleId IdType="pii">481591</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collaborators -C-CI. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351–2380. doi:10.1016/S0140-6736(22)00484-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00484-6</ArticleId><ArticleId IdType="pmc">PMC8993157</ArticleId><ArticleId IdType="pubmed">35405084</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards F, Kodjamanova P, Chen X, et al. Economic Burden of COVID-19: a Systematic Review. Clinicoecon Outcomes Res. 2022;14:293–307. doi:10.2147/CEOR.S338225</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEOR.S338225</ArticleId><ArticleId IdType="pmc">PMC9060810</ArticleId><ArticleId IdType="pubmed">35509962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA, Zonta F, Levitt M. Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy. medRxiv. 2023;2023:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10407651</ArticleId><ArticleId IdType="pubmed">36691703</ArticleId></ArticleIdList></Reference><Reference><Citation>Paton RS, Overton CE, Ward T. The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England. Sci Transl Med. 2022;14(652):eabo5395. doi:10.1126/scitranslmed.abo5395</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5395</ArticleId><ArticleId IdType="pmc">PMC9097877</ArticleId><ArticleId IdType="pubmed">35503007</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675. doi:10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudima G, Kofiadi I, Shilovskiy I, et al. Antiviral Therapy of COVID-19. Int J Mol Sci. 2023;24(10):8867. doi:10.3390/ijms24108867</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108867</ArticleId><ArticleId IdType="pmc">PMC10218869</ArticleId><ArticleId IdType="pubmed">37240213</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, de Wit E. Antiviral agents for the treatment of COVID-19: progress and challenges. Cell Rep Med. 2022;3(3):100549. doi:10.1016/j.xcrm.2022.100549</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100549</ArticleId><ArticleId IdType="pmc">PMC8831133</ArticleId><ArticleId IdType="pubmed">35474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N, Hayden R, Hills T, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023;19(1):38–52. doi:10.1038/s41581-022-00642-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M, Mengato D, Sasset L, et al. Molnupiravir and Nirmatrelvir/Ritonavir: tolerability, Safety, and Adherence in a Retrospective Cohort Study. Viruses. 2023;15(2):384. doi:10.3390/v15020384</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020384</ArticleId><ArticleId IdType="pmc">PMC9962206</ArticleId><ArticleId IdType="pubmed">36851598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Chang J. The first Chinese oral anti-COVID-19 drug Azvudine launched. Innovation. 2022;3(6):100321. doi:10.1016/j.xinn.2022.100321</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xinn.2022.100321</ArticleId><ArticleId IdType="pmc">PMC9461232</ArticleId><ArticleId IdType="pubmed">36106026</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N, Yang J, Zheng B, et al. The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses. J Virol. 2020;94(9):e00204–00220. doi:10.1128/JVI.00204-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00204-20</ArticleId><ArticleId IdType="pmc">PMC7163137</ArticleId><ArticleId IdType="pubmed">32075935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Peng Y, Yu W, et al. Mechanistic Insight into Antiretroviral Potency of 2’-Deoxy-2’-beta-fluoro-4’-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. J Med Chem. 2020;63(15):8554–8566. doi:10.1021/acs.jmedchem.0c00940</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00940</ArticleId><ArticleId IdType="pubmed">32678592</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J. 4′-Modified Nucleosides for Antiviral Drug Discovery: achievements and Perspectives. Acc Chem Res. 2022;55(4):565–578. doi:10.1021/acs.accounts.1c00697</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.1c00697</ArticleId><ArticleId IdType="pubmed">35077644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct Target Ther. 2020;5(1):236. doi:10.1038/s41392-020-00351-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00351-z</ArticleId><ArticleId IdType="pmc">PMC7547293</ArticleId><ArticleId IdType="pubmed">33040075</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:115503. doi:10.1016/j.ejmech.2023.115503</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115503</ArticleId><ArticleId IdType="pmc">PMC10193775</ArticleId><ArticleId IdType="pubmed">37229831</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva RM, Abreu Cabral P G, de Souza SB, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med. 2023;10:1143485. doi:10.3389/fmed.2023.1143485</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1143485</ArticleId><ArticleId IdType="pmc">PMC10053779</ArticleId><ArticleId IdType="pubmed">37007788</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Tian F. Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis. Heliyon. 2023;9(9):e20153. doi:10.1016/j.heliyon.2023.e20153</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20153</ArticleId><ArticleId IdType="pmc">PMC10559905</ArticleId><ArticleId IdType="pubmed">37809649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Luo H, Yu Z, et al. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. Adv Sci. 2020;7(19):e2001435. doi:10.1002/advs.202001435</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202001435</ArticleId><ArticleId IdType="pmc">PMC7404576</ArticleId><ArticleId IdType="pubmed">35403380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xie H, Wang L, et al. Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis. Virol J. 2024;21(1):46. doi:10.1186/s12985-024-02316-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-024-02316-y</ArticleId><ArticleId IdType="pmc">PMC10893615</ArticleId><ArticleId IdType="pubmed">38395970</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza SB, Cabral PGA, da Silva RM, et al. Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients. Front Med. 2023;10:1215916. doi:10.3389/fmed.2023.1215916</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1215916</ArticleId><ArticleId IdType="pmc">PMC10620601</ArticleId><ArticleId IdType="pubmed">37928473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Wang Z, Jiang C, et al. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study. J Med Virol. 2023;95(7):e28947. doi:10.1002/jmv.28947</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28947</ArticleId><ArticleId IdType="pubmed">37470209</ArticleId></ArticleIdList></Reference><Reference><Citation>General Office of the National Health Commission. Diagnosis and treatment protocol for COVID-19 in China (trial version 10). Available from: http://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm. 2023, Accessed February
1, 2024.</Citation></Reference><Reference><Citation>Sun Y, Jin L, Dian Y, et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 2023;59:101981. doi:10.1016/j.eclinm.2023.101981</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101981</ArticleId><ArticleId IdType="pmc">PMC10167478</ArticleId><ArticleId IdType="pubmed">37193346</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Yang M, Xu L, et al. Azvudine and mortality in patients with coronavirus disease 2019: a retrospective cohort study. Int Immunopharmacol. 2023;124:110824. doi:10.1016/j.intimp.2023.110824</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110824</ArticleId><ArticleId IdType="pubmed">37633242</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lin Y, Lu H, et al. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: a retrospective cohort study. Diagn Microbiol Infect Dis. 2024;109(4):116353. doi:10.1016/j.diagmicrobio.2024.116353</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2024.116353</ArticleId><ArticleId IdType="pubmed">38776665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapar A, Xie S, Guo Z, et al. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study. Expert Rev Anti Infect Ther;2024. 1–9. doi:10.1080/14787210.2024.2362900</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2024.2362900</ArticleId><ArticleId IdType="pubmed">38822541</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao J, Fan R, Guo C, et al. Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China. Microorganisms. 2023;11(7):1859. doi:10.3390/microorganisms11071859</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11071859</ArticleId><ArticleId IdType="pmc">PMC10383482</ArticleId><ArticleId IdType="pubmed">37513031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang S, Fu B, Geng Y, et al. Azvudine therapy of common COVID-19 in hemodialysis patients. J Med Virol. 2023;95(8):e29007. doi:10.1002/jmv.29007</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29007</ArticleId><ArticleId IdType="pubmed">37522276</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JL, Li YH, Wang LL, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):414. doi:10.1038/s41392-021-00835-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00835-6</ArticleId><ArticleId IdType="pmc">PMC8646019</ArticleId><ArticleId IdType="pubmed">34873151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng N, Li R, Li Y, et al. Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect. Acta Pharm Sin B. 2024;14(7):3140–3154. doi:10.1016/j.apsb.2024.03.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2024.03.032</ArticleId><ArticleId IdType="pmc">PMC11252455</ArticleId><ArticleId IdType="pubmed">39027259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis. 2020;96:131–135. doi:10.1016/j.ijid.2020.04.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.04.086</ArticleId><ArticleId IdType="pmc">PMC7196544</ArticleId><ArticleId IdType="pubmed">32376308</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi:10.1038/s41368-020-0074-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-020-0074-x</ArticleId><ArticleId IdType="pmc">PMC7039956</ArticleId><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YC, Liang WG, Chen FW, et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169(8):4288–4297. doi:10.4049/jimmunol.169.8.4288</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.169.8.4288</ArticleId><ArticleId IdType="pubmed">12370360</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847. doi:10.1002/ajh.25829</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25829</ArticleId><ArticleId IdType="pmc">PMC7262337</ArticleId><ArticleId IdType="pubmed">32282949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Wang W, Wu D, et al. Peripheral Lymphocyte Count and Viral Clearance in COVID-19. J Coll Physicians Surg Pak. 2022;32(12):1637–1639.</Citation><ArticleIdList><ArticleId IdType="pubmed">36474394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Zhang Y, Wang Z, et al. Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: a real-world retrospective study. Heliyon. 2024;10(9):e30619. doi:10.1016/j.heliyon.2024.e30619</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e30619</ArticleId><ArticleId IdType="pmc">PMC11096973</ArticleId><ArticleId IdType="pubmed">38756599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Wang Z, Wang C, et al. Cost-effectiveness of Azvudine for High-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in China. Clin Ther. 2024;46(9):e1–e5. doi:10.1016/j.clinthera.2024.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2024.07.009</ArticleId><ArticleId IdType="pubmed">39155175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>